Clinical Trials Browser

Phase 3 × Hematologic Diseases × Myeloid × Clear all

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02055781 2021-11-18

PAC326

Phase 3 Terminated

311 enrolled 12 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02218047 2021-06-01

CONTI-PV

Phase 3 Completed

170 enrolled

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 3 Completed

536 enrolled 24 charts 1 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Phase 3 Terminated

327 enrolled 11 charts

Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT01511289 2016-02-24

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Phase 3 Completed

242 enrolled

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02523638 2016-02-17

PEN-PV

Phase 3 Completed

30 enrolled

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3 Terminated

307 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

OPTIC-2L

PAC326

RESPONSE-2

CONTI-PV

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

PEN-PV

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)